Blog

Can Good Cholesterol Harm Your Glaucoma Risk? For years, high-density lipoprotein (HDL), often referred to as “good cholesterol,” has been celebrated for its role in heart health. It helps remove low-density lipoprotein (LDL), or “bad cholesterol,” from the bloodstream, reducing the risk of cardiovascular disease. But could there be a downside to having high HDL

PreserFlo MicroShunt Complications Lead to Corneal Damage and Surgical Revision The PreserFlo MicroShunt has been widely adopted as a minimally invasive surgical option for glaucoma patients, offering an alternative to traditional trabeculectomy. While the device has shown promise in reducing intraocular pressure (IOP), emerging reports highlight complications such as corneal damage and the need for

Dr. Oluwatosin Smith Advocates Early Glaucoma Care at ASCRS 2025 At the prestigious American Society of Cataract and Refractive Surgery (ASCRS) 2025 conference, renowned ophthalmologist Dr. Oluwatosin Smith delivered a compelling keynote address on the critical importance of early glaucoma detection and intervention. With glaucoma being a leading cause of irreversible blindness worldwide, Dr. Smith’s

Early Diagnosis of Childhood Glaucoma with Swept-Source AS-OCT Childhood glaucoma is a rare but serious eye condition that can lead to permanent vision loss if not diagnosed and treated early. Traditional diagnostic methods often fall short in detecting subtle changes in the anterior segment of the eye, especially in young children. However, advancements in imaging

iStent Infinite Trial: Key Clinical Insights for Glaucoma Treatment Glaucoma remains one of the leading causes of irreversible blindness worldwide, affecting millions of people. While traditional treatments like eye drops, laser therapy, and trabeculectomy have been the mainstay, minimally invasive glaucoma surgeries (MIGS) are revolutionizing patient care. Among these, the iStent Infinite has emerged as

Glaucoma Treatment Market to Hit USD 14.1 Billion by 2033 with 5.35% CAGR Growth The global glaucoma treatment market is poised for significant expansion, projected to reach USD 14.1 billion by 2033, growing at a compound annual growth rate (CAGR) of 5.35%. This growth is fueled by rising prevalence of glaucoma, advancements in treatment options,

Brandon Capital and Labor’s NRF Invest $40M in Glaucoma Biotech PolyActiva The biotechnology sector continues to attract significant investment as innovative companies push the boundaries of medical science. In a major development, Brandon Capital and Labor’s National Reconstruction Fund (NRF) have jointly invested $40 million in PolyActiva, an Australian biotech firm specializing in glaucoma treatments.

Surge in Three Major Eye Diseases Linked to Blindness In recent years, the prevalence of eye diseases leading to blindness has seen a concerning rise. With aging populations, increased screen time, and environmental factors, experts warn that conditions like glaucoma, age-related macular degeneration (AMD), and diabetic retinopathy are becoming more widespread. Understanding these diseases, their

Innovative Minimally Invasive Glaucoma Treatments in Development Glaucoma is a leading cause of irreversible blindness worldwide, affecting millions of people. Traditional treatments, such as eye drops, laser therapy, and invasive surgeries, have been the mainstay for managing intraocular pressure (IOP). However, these methods often come with limitations, including side effects, compliance issues, and variable efficacy.